The antiproliferative properties of a series of structurally-related
gold(I) and
silver(I) linear complexes inspired to the clinically established
gold-based drug
auranofin were investigated in A2780
ovarian cancer cells and in their
auranofin (A2780/AF-R) and
cisplatin (A2780/CDDP-R) resistant counterparts. In A2780 cells and in the
cisplatin-resistant subline,
gold-based analogues manifested a cytotoxicity profile comparable or superior to
auranofin, while the
silver-based analogues were less active; both
gold and
silver complexes overcame
cisplatin resistance. Yet, a high degree of cross resistance toward
gold analogues was noticed in A2780/AF-R cells. In the same cell line cross-resistance for
silver analogues was also observed, though lower. All
metal complexes were scrutinized for their ability to inhibit
thioredoxin reductase (TrxR), the putative primary target for
auranofin: overall,
gold compounds were more potent TrxR inhibitors than the corresponding
silver compounds, probably, as the consequence of the stronger binding of
gold to the active site
selenocysteine residue. These results highlight that the thiosugar
ligand of
auranofin is not essential for cytotoxicity while the nature of the
metal center (
gold/
silver) plays a relevant role in its modulation. In addition, a rather clear correlation was found between cytotoxic potency of tested compounds and their ability to inhibit TrxR activity, being
gold compounds more effective than
silver analogues. However, the residual TrxR activity, measured in A2780 cells treated with the half-maximal inhibitory concentrations of various
metal complexes, resulted far higher than expected. These results suggest that additional cytotoxic mechanisms must be operative. The implications of these results are discussed.